Recent Updates
Recently added Catalysts

Daraxonrasib

Phase 3FDA approved

NSCLC (Non-small Cell Lung Cancer) | Small Molecules | Oncology |Revolution Medicines, Inc.|Trials Updated: Nov 6, 2026

Daraxonrasib development status

FDA approval on record Aug 26, 2026 as Rasonque
Approval holderRevolution Medicines
ApplicationNDA220910
Highest phase Phase 3
Registered trials 19 across 7 sponsors since May 2022

Daraxonrasib target and mechanism

Molecular targetRAS
Target classProtein
ModalitySmall Molecules

Also known as RMC-6236, RAS inhibitor

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials11
Total Enrollment5,269

FDA Designations

BREAKTHROUGH_THERAPY

Daraxonrasib clinical trials

Daraxonrasib · 11 trials · 32 indications

Phase 3 5Phase 2 1Phase 1/2 3Phase 1 2
NCT07805954Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaPancreatic Cancer
RECRUITING400 Analytics
NCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPancreatic Cancer
RECRUITING900 Analytics
NCT07252232Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Cancer
RECRUITING500 Analytics
NCT06881784Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NSCLC (Non-small Cell Lung Cancer)
RECRUITING590 Analytics
NCT06625320Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Cancer
ACTIVE NOT_RECRUITING500 Analytics
PHASE3RECRUITING
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Pancreatic CancerUnlock trial analytics
PHASE3RECRUITING
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic CancerUnlock trial analytics
PHASE3RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic CancerUnlock trial analytics
PHASE3RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NSCLC (Non-small Cell Lung Cancer)Unlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic CancerUnlock trial analytics

Study Endpoints

Primary Endpoints

Progression free survival (PFS)
Up to approximately 4 years

PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by Investigator.

Overall survival (OS)
Up to approximately 4 years

OS is defined as the time from randomization until death from any cause.

Disease-Free Survival (DFS) per Investigator
Up to approximately 5 years

DFS defined as the time from randomization until disease recurrence or death from any cause, whichever occurs first. Recurrence is per response evaluation criteria in solid tumors (RECIST) v1.1 as assessed by Investigator.

Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C)
Up to approximately 4 years

PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by BICR.

Overall survival (OS) in the RAS G12X-C population
Up to approximately 4 years

OS is defined as the time from randomization until death from any cause.

Progression free survival (PFS) in the RAS G12-mutant population
Up to approximately 3 years

PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by blinded independent central review (BICR)

Overall survival (OS) in the RAS G12-mutant population
Up to approximately 3 years

OS is defined as the time from randomization until death from any cause.

Objective Response (ORR)
4 years

ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) based on the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Subjects who discontinue due to toxicity or clinical progression prior to post-baseline tumor assessments will be considered as non-responders.

Number of patients with adverse events (AEs)
Up to approximately 4 years

Number of patients with AEs as assessed by CTCAE v5.

Changes in vital signs
Up to approximately 4 years

Number of patients with changes in vital signs.

Changes in clinical laboratory test values
Up to approximately 4 years

Number of patients with changes in clinical laboratory test values.

Dose Limiting Toxicities
28 days

Number of patients with dose limiting toxicities

Adverse events (Subprotocols A-F)
Up to 3 years

Evaluate the safety and tolerability in the study population characterized by incidence, abnormal laboratory assessments, severity, and seriousness of adverse events in relation to the study treatment.

Dose limiting toxicities (Subprotocols A-F)
28 days

Number of participants with dose limiting toxicities

Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)(Subprotocol G)
Up to 3 years
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs
up to 2.5 years
Number of Participants with Dose-Limiting Toxicity (DLT)
21 days
Successful Receipt of Surgery Rate
After 6- or 12-weeks of neoadjuvant therapy

Proportion of participants who complete neoadjuvant darazonrasib therapy and then attempt surgery.

Safety and tolerability of SNV1521 plus daraxonrasib: treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities
through study completion, an average of 1 year

Number, type, and severity of treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities in participants receiving SNV1521 plus daraxonrasib, used to identify doses suitable for further study, classified and graded according to CTCAE v6.0 and protocol-defined DLT criteria

Secondary Endpoints

PFS by blinded independent central review (BICR)
Up to approximately 4 years
Objective response rate (ORR)
Up to approximately 4 years
Duration of response (DOR)
Up to approximately 4 years
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm A: daraxonrasib + zoldonrasibEXPERIMENTALcombination of study drugs
Arm B: gemcitabine and nab-paclitaxelEXPERIMENTALchemotherapy
Arm A: daraxonrasibEXPERIMENTALstudy drug
Arm B: daraxonrasib + gemcitabine and nab-paclitaxelEXPERIMENTALstudy drug in combination with chemotherapy
Arm C: gemcitabine and nab-paclitaxelACTIVE_COMPARATORSOC chemotherapy
daraxonrasibEXPERIMENTALstudy drug
SOC ObservationNO_INTERVENTIONPatients randomized to the comparator control arm will receive SOC observation.
docetaxelACTIVE_COMPARATORPatients randomized to the comparator control arm will receive docetaxel as the standard of care therapy.
RMC-6236EXPERIMENTALStudy drug
Investigator's choice of standard of care therapyACTIVE_COMPARATORPatients randomized to Investigator's choice of standard of care chemotherapy will receive one of the following four treatments: * Gemcitabine and nab-paclitaxel (GnP) * Oxaliplatin, leucovorin, irinotecan, and 5-FU (Modified FOLFIRINOX: mFOLFIRINOX) * Liposomal irinotecan (Nal-IRI + 5-FU/LV) * Oxaliplatin, leucovorin and 5-FU IV (FOLFOX)
Arm A: Daraxonrasib + Ivonescimab CombinationEXPERIMENTALDose Exploration and Dose Expansion (+ Carboplatin/Cisplatin + Pemetrexed)
Arm B: Elironrasib + Ivonescimab CombinationEXPERIMENTALDose Exploration and Dose Expansion. Dose Expansion will include two separate cohorts: Cohort B1 (+ daraxonrasib) and Cohort B2 (+ Carboplatin/Cisplatin + Pemetrexed).
Arm C: Zoldonrasib + Ivonescimab CombinationEXPERIMENTALDose Exploration and Dose Expansion. Dose Expansion will include two separate cohorts: Cohort C1 and Cohort C2 (+ Cetuximab).
Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDACEXPERIMENTALRMC-6236 (QD) and bevacizumab with 5-fluorouracil-based regimens
Subprotocol B: RAS-mutated unresectable or metastatic CRC or metastatic PDACEXPERIMENTALRMC-6236 (QD) and cetuximab with or without mFOLFOX6
Subprotocol C: metastatic PDACEXPERIMENTALRMC-6236 (QD) and gemcitabine with nab-paclitaxel
Subprotocol D: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDACEXPERIMENTALRMC-9805 (QD or BID) with or without RMC-6236 (QD), and bevacizumab with 5-fluorouracil- based regimens
Subprotocol E: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDACEXPERIMENTALRMC-9805 (QD or BID) with or without RMC-6236 (QD), and cetuximab with or without mFOLFOX6
Subprotocol F: RAS G12D-mutated metastatic PDACEXPERIMENTALRMC-9805 (QD or BID) with or without RMC-6236 (QD), and gemcitabine with nab-paclitaxel
Subprotocol G: RAS G12D-mutated metastatic CRCEXPERIMENTALRMC-9805 (QD) and cetuximab with FOLFIRI
Experimental: RMC-6236EXPERIMENTALEnrollment into dose exploration may be from any advanced solid tumor type with KRAS p.G12 mutations. Enrollment into dose expansion/optimization may be from groups consisting of patients with a single histotype/genotype (for example, KRAS G12-mutated NSCLC, PDAC, CRC, RAS mutant NSCLC, Melanoma, gynecological cancer or other solid tumors not previously specified). RAS mutant is defined as any nonsynonymous mutation of KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)
Cohort A Perioperative DaraxonrasibEXPERIMENTALParticipants receive oral daraxonrasib once daily at a predetermined dose for 6 weeks before surgery, followed by a surgical planning interval, surgical resection, adjuvant chemotherapy with or without radiation per institutional standard and investigator discretion, and optional adjuvant daraxonrasib after completion of adjuvant therapy.
Cohort B Perioperative DaraxonrasibEXPERIMENTALParticipants receive oral daraxonrasib once daily at a predetermined dose for 12 weeks before surgery, followed by a surgical planning interval, surgical resection, adjuvant chemotherapy with or without radiation per institutional standard and investigator discretion, and optional adjuvant daraxonrasib after completion of adjuvant therapy.
EscalationEXPERIMENTALParticipants in this arm will take SNV1521 by mouth together with a RAS-targeted cancer medicine. The dose of SNV1521 will be increased in small steps to find a safe and tolerable dose of the combination in people with advanced pancreatic cancer.

Interventions

NameTypeDescription
daraxonrasibDRUGoral tablets
gemcitabineDRUGintravenous (IV) infusion
nab-paclitaxelDRUGIV infusion
zoldonrasibDRUGoral tablets
docetaxelDRUGintravenous (IV) infusion
RMC-6236DRUGOral Tablets
IrinotecanDRUGIV infusion
Liposomal irinotecanDRUGIV infusion
5-fluorouracilDRUGIV infusion
leucovorinDRUGIV infusion
OxaliplatinDRUGIV infusion
ElironrasibDRUGoral tablets
IvonescimabDRUGIV infusion
Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)DRUGIV infusion
cetuximab (Cohort C2 Only)DRUGIV infusion
Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)DRUGIV infusion
Daraxonrasib (Cohort B1 only)DRUGoral tablets
mFOLFOX6 regimenDRUGIV infusion
bevacizumabDRUGIV infusion
mFOLFIRINOX regimenDRUGIV infusion
cetuximabDRUGIV infusion
RMC-9805DRUGOral Tablet
FOLFIRI regimenDRUGIV infusion
Surgical ResectionPROCEDUREProtocol-planned surgery performed after neoadjuvant daraxonrasib treatment and surgical planning.
Adjuvant ChemotherapyDRUGPost-surgery chemotherapy administered per institutional standard and investigator/physician discretion.
Adjuvant Radiation TherapyRADIATIONPost-surgery radiation therapy may be given with adjuvant chemotherapy according to institutional standard and investigator/physician discretion.
SNV1521DRUGSNV1521 is an oral investigational anticancer drug. In this study, SNV1521 is administered at different dose levels together with the RAS inhibitor daraxonrasib in adults with locally advanced unresectable or metastatic pancreatic cancer.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Histologically or cytologically confirmed pancreatic adenocarcinoma, including adenosquamous carcinoma, not previously treated in the locally ad...

Countries:United StatesAustraliaAustriaBelgiumBrazilCanadaGermanyHong KongItalyJapanNetherlandsSingaporeSouth KoreaSpainTaiwanUnited KingdomFrancePuerto RicoIrelandNew ZealandPolandSwitzerland
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 6, 2026NCT07805954lastUpdatePostDate: changed
LOWNov 6, 2026NCT06881784lastUpdatePostDate: changed
LOWNov 4, 2026NCT07397338lastUpdatePostDate: changed
LOWNov 4, 2026NCT07397338lastUpdatePostDate: changed
LOWOct 27, 2026NCT07898813NEW_TRIAL: changed
LOWOct 27, 2026NCT07756281Status: NOT_YET_RECRUITING → RECRUITING
LOWOct 27, 2026NCT07898813NEW_TRIAL: changed
LOWOct 27, 2026NCT07756281Status: NOT_YET_RECRUITING → RECRUITING
LOWOct 24, 2026NCT07252232lastUpdatePostDate: changed
LOWOct 24, 2026NCT07252232lastUpdatePostDate: changed
LOWOct 24, 2026NCT07252232lastUpdatePostDate: changed
LOWOct 24, 2026NCT07252232lastUpdatePostDate: changed
LOWOct 16, 2026NCT07805954lastUpdatePostDate: changed
LOWOct 16, 2026NCT07805954lastUpdatePostDate: changed
LOWOct 2, 2026NCT07491445lastUpdatePostDate: changed
LOWOct 2, 2026NCT07491445lastUpdatePostDate: changed
LOWSep 30, 2026NCT07491445lastUpdatePostDate: changed
LOWSep 30, 2026NCT07491445lastUpdatePostDate: changed
LOWSep 29, 2026NCT06881784lastUpdatePostDate: changed
LOWSep 29, 2026NCT06881784lastUpdatePostDate: changed

Frequently asked questions about Daraxonrasib

What is daraxonrasib?

Daraxonrasib is an investigational small molecule RAS inhibitor being developed by Revolution Medicines, Inc. for advanced solid tumors. It is being studied in pancreatic cancer, biliary tract cancers, colorectal cancer, and non-small cell lung cancer. Daraxonrasib is also known as RMC-6236 and remains in clinical development.

What is daraxonrasib used for?

Daraxonrasib is being studied for advanced solid tumors, including pancreatic cancer, biliary tract cancers, colorectal cancer, and non-small cell lung cancer. Trials include resectable pancreatic ductal adenocarcinoma, metastatic KRAS G12D-mutated pancreatic adenocarcinoma, and recurrent KRAS-mutant biliary tract cancer.

What does daraxonrasib target?

Daraxonrasib targets RAS, a protein class of signaling molecules. It is a small molecule designed to inhibit RAS. The clinical program is biomarker selected, with trials enrolling patients whose tumors carry KRAS mutations, including KRAS G12D-mutated pancreatic adenocarcinoma and KRAS-mutant biliary tract cancer.

Who is developing daraxonrasib?

Daraxonrasib is being developed by Revolution Medicines, Inc., which trades under the ticker RVMD. The company is running the daraxonrasib clinical program across several solid tumor indications, including pancreatic cancer and biliary tract cancers.

What phase is daraxonrasib in?

Daraxonrasib is in Phase 1 development overall, with additional studies at later stages. A Phase 3 trial, NCT07805954, is recruiting and evaluates zoldonrasib plus daraxonrasib versus gemcitabine and nab-paclitaxel in first-line metastatic KRAS G12D-mutated pancreatic adenocarcinoma. Daraxonrasib is investigational and not approved.

What clinical trials is daraxonrasib in?

Daraxonrasib trials include NCT07898813 in resectable pancreatic ductal adenocarcinoma, NCT07805954 in first-line metastatic KRAS G12D-mutated pancreatic adenocarcinoma, NCT07793253 in recurrent KRAS-mutant biliary tract cancer, and NCT07756281, a first-in-human study with SNV1521 in advanced pancreatic cancer.

Is daraxonrasib the same as RMC-6236?

Yes, daraxonrasib is the same drug as RMC-6236. RMC-6236 is an alternative name for daraxonrasib, the investigational RAS inhibitor from Revolution Medicines, Inc. being studied in pancreatic cancer, biliary tract cancers, colorectal cancer, and non-small cell lung cancer.